Rocaltrol Articles
13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10
4 February 2010
Vit D may halt lung function decline
2 June 2009
Clobex/Vectical "effective" in managing psoriasis
16 March 2009
Fontus Pharma acquires drug from Roche
23 June 2008
Encouraging Ph I data for Hybrigenics' inecalcitol
16 April 2007
Novacea's Asentar improves survival in AIPC
26 February 2007
Japan stock market week to March 27, 2006
3 April 2006
Hybrigenics acquires Vit D analog inecalcitol
13 February 2006
BCI advances LR-103 into kidney disease trial
16 May 2005
Sicor re-acquires Calcitrol rights from aaiPharma
10 January 2005
Cytochroma selects psoriasis drug candidate
29 September 2003
APP to sell Calcijex generic in USA
20 January 2003
Novacea to test MDS compound in Phase II
20 January 2003
Vitamin D boosts Taxotere efficacy in prostate cancer
6 January 2003
Teva gets first OK for generic Rocaltrol in USA
15 October 2001
Kirin acquires Japanese rights to Roche's Calcitriol
2 November 2000
FDA OK's InterMune's osteopetrosis therapy
15 February 2000
Abbott's Paricalcitol Is Approved In The USA
30 April 1998
Nicholas Piramal To Focus On Pharma Business
27 April 1998
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Roche: Rocaltrol launch
16 October 1995
Congress Faces Generic Drug Pressure Over GATT
24 July 1995
1994 Brings Israel's BTG Closer To Goals
3 July 1995
BTG's Silkis Launched In Holland
12 June 1995
Calcitriol Price Discrimination Under Fire In Australia
13 February 1995
NIPPON ROCHE'S SALES CLIMB IN 1993
28 February 1994
SALES "EXCELLENT" AT NIPPON ROCHE
22 March 1993
SOLVAY'S HEALTH CARE BUSINESS REVIEWED
25 January 1993
CALCITRIOL BENEFIT FOR OSTEOPOROSIS
10 February 1992
Showing 1-35 of 35 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
